NIH Guide to Grants and Contracts

The NIH Guide for Grants and Contracts is our official publication for NIH grant policies, guidelines and funding opportunities. We publish daily, and issue a table of contents weekly. Learn more about the NIH Guide and subscribe today!

The old advanced search is still avaliable.

New Features:

  • Tabular view - You can now view the search results in table format.
  • Export to excel - Search results can now be exported to excel for reporting purposes.

Results: 26 to 50 of 1430

Display Results as:

Functional Wellness in HIV: Maximizing the Treatment Cascade (R01) - PA-15-133

Organization: NINR 

Posting Date: 03-05-2015 

Expiration Date: 01-25-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV.  

Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01) - PA-15-135

Organization: NIDCR 

Posting Date: 03-09-2015 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: The purpose of this funding opportunity announcement (FOA) is twofold: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.  

Alcohol Impairment of Immune Function, Host Defense and Tissue Homeostasis (R01) - PA-15-159

Organization: NIAAA 

Posting Date: 03-26-2015 

Expiration Date: 01-25-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) invites applications from researchers with broad expertise to study the consequences of alcohol consumption on immune function with a goal toward improving the outcome of patients who abuse alcohol.  

New Directions in Hematology Research (SHINE-II) (R01) - PAS-15-168

Organization: NIDDK 

Posting Date: 04-01-2015 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) is intended to promote innovative research initiatives that explore high impact, new directions of inquiry relevant to the hematology research mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).NIDDK invites investigator-initiated grant applications for basic or pre-clinical, proof of principle research projects that are tightly focused and directed at validating novel concepts and approaches that promise to open up new pathways for discovery.Research applications submitted under this FOA should be more limited in scope (a single central aim) and duration (1-3 years) than typical R01 grant applications.  

Alzheimer's Drug-Development Program (U01) - PAR-15-174

Organization: NIA 

Posting Date: 04-02-2015 

Expiration Date: 01-25-2018 

Activity Code: U01 

Summary: The goal of this Funding Opportunity Announcement (FOA) is to provide funding support for the pre-clinical and early stage clinical (Phase I) development ofsmall-molecule and biologic therapeutic agents that prevent Alzheimer's disease (AD), slow its progression or treat its cognitive and behavioral symptoms.Participants in this program will receive funding for therapy development activities such as medicinal chemistry, pharmacokinetics (PK), Absorption, Distribution, Metabolism, Excretion, Toxicology (ADMET), efficacy in animal models, formulation development, chemical synthesis under Good Manufacturing Practices (GMP), Investigational New Drug (IND) enabling studies and initial Phase I clinical testing. This program does not support research on basic mechanisms of disease, development of biomarkers, devices, non-pharmacological interventions (e.g., exercise, diet, cognitive training), repurposed drugs and combinations therapies or, discovery activities such as high throughput screening and hit optimization. 

Phenotypic and Functional Studies on FOXO3 Human Longevity Variants to Inform Potential Therapeutic Target Identification Research (R01) - PAR-15-175

Organization: NIA 

Posting Date: 04-03-2015 

Expiration Date: 01-25-2018 

Activity Code: R01 

Summary: The focus of this Funding Opportunity Announcement (FOA) is on in vivo human studies, and in vitro studies on human cells or tissues, aimed at potential identification of therapeutic targets or and/or testing of interventions for healthy aging. Potential therapeutic targets include FOXO3 itself and upstream and downstream regulators in pathways mediated by FOXO3. The range of research areas of interest in this FOA includes studies that: 1) examine in vivo phenotypic effects of human FOXO3 variants, and/or 2) elucidate effects of these variants on cellular functions and the pathways that mediate them, and/or 3) identify and evaluate candidate therapeutic targets (e.g., target validation studies, testing of candidate compounds) for potential interventions based on FOXO3 functional pathways.  

Integrated Food Defense & Emergency Response Cooperative Agreement Program IFD&ER (U18) - RFA-FD-15-022

Organization: FDA 

Posting Date: 05-04-2015 

Expiration Date: 04-03-2019 

Activity Code: U18 

Summary: The Integrated Food Defense & Emergency Response Cooperative Agreement Program (IFD&ER CAP) grant awards are designed to generate food defense tools and resources that are easily replicated and can complement, aid in the development of, and/or improve State, local, Tribal and territorial (SLTT) food defense programs through unique, innovative, and reproducible projects . The known overlap between food safety (unintentional contamination) and food defense (intentional contamination) is extensive. And the pools of resources available are vast and sometimes difficult to locate and implement. As the Food Safety Modernization Act (FSMA) recognizes the evolution of the relationship between food safety and food defense, it is critical that these programs be integrated to the maximum extent possible in order to ensure the most efficient use of resources, as well as to optimize responses to incidents and events. 

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R01) - PA-15-251

Organization: NIDA 

Posting Date: 05-08-2015 

Expiration Date: 05-08-2018 

Activity Code: R01 

Summary: This Funding Opportunity Announcement (FOA) encourages R01 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.  

Integrated Food Safety System Online Collaboration Development (U18) - RFA-FD-15-024

Organization: FDA 

Posting Date: 05-06-2015 

Expiration Date: 07-16-2105 

Activity Code: U18 

Summary: The Office of Regulatory Affairs, in coordination with FDAs Office of Foods, Center for Food Safety and Applied Nutrition, and Center for Veterinary Medicine, is soliciting a cooperative grant proposal to expedite program development to support critical federal-state collaboration necessary to plan and implement an integrated food safety system. 

Prevention Research in Mid-Life Adults (R21) - PA-15-097

Organization: NINR 

Posting Date: 01-22-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) seeks to stimulate research on mid-life adults (those 50 to 64 years of age) that can inform efforts to optimize health and wellness as individuals age, and prevent illness and disability in later years. 

Functional Wellness in HIV: Maximizing the Treatment Cascade (R21) - PA-15-134

Organization: NINR 

Posting Date: 03-05-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: The National Institute of Nursing Research (NINR) seeks to promote the development of HIV interventions which target opportunities to improve the delivery of healthcare across the continuum of care for persons infected with HIV. 

International Research Collaboration on Drug Abuse and Addiction Research (R03) - PA-15-141

Organization: NIDA 

Posting Date: 03-17-2015 

Expiration Date: 01-25-2018 

Activity Code: R03 

Summary: This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas(http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The NIH R03 activity code supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding. The R03 activity code supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. 

International Research Collaboration on Drug Abuse and Addiction Research (R21) - PA-15-143

Organization: NIDA 

Posting Date: 03-17-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that take advantage of special opportunities that exist outside the United States. Special opportunities include access to unusual talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery. Projects should have relevance to the mission of NIDA and where feasible should address NIDAs international scientific priority areas (http://www.drugabuse.gov/international/research-priorities). While the priorities will change from year to year, in FY15 priority areas include: linkages between HIV/AIDS and drug abuse; prevention, initiation, and treatment of nicotine and tobacco use (especially among vulnerable populations such as children, adolescents, pregnant women, and those with co-morbid disorders); the neuroscience of marijuana and cannabinoids; and the effect of changes in laws and policies on marijuana and its impact. The R21 activity code is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough in a particular area, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on a field of biomedical, behavioral, or clinical research. Projects of limited cost or scope that use widely accepted approaches and methods within well-established fields are better suited for the R03 small grant activity code. 

AHRQ Small Research Grant Program (R03) - PA-15-147

Organization: AHRQ 

Posting Date: 03-19-2015 

Expiration Date: 07-17-2018 

Activity Code: R03 

Summary: This FOA encourages Small Research Grant (R03) applications, and expresses AHRQ priority areas of interest for ongoing small research projects. The R03 grant mechanism supports different types of health services research projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology. 

Pilot and Feasibility Clinical Research Grants in Kidney Diseases (R21) - PAR-15-161

Organization: NIDDK 

Posting Date: 03-27-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to kidney disease research. Studies should address important clinical and translational questions and are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of diagnosis, prevention, or treatment of kidney diseases. 

Pilot and Feasibility Clinical Research Grants in Urologic Disorders (R21) - PAR-15-162

Organization: NIDDK 

Posting Date: 03-27-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) is to support Exploratory/Developmental Research Grants (R21) that propose small scale or pilot and feasibility clinical and translational research studies, including epidemiological studies or clinical trials related to urologic disorders research. Studies should address important clinical and translational questions that are potentially of high clinical and public health impact. It is anticipated that some projects supported by these grants may lead to full-scale clinical studies including diagnostic strategies, epidemiological studies, or randomized clinical trials of prevention, diagnosis or treatment of urologic disorders. 

Exploratory/Developmental Clinical Research Grants in Obesity (R21) - PA-15-163

Organization: NIDDK 

Posting Date: 03-27-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) encourages research grant applications from institutions/organizations that propose to conduct exploratory/developmental clinical studies that will accelerate the development of effective interventions for prevention or treatment of overweight or obesity in adults and/or children. Exploratory epidemiological research with a goal of informing translational/clinical research will also be supported within this program.  

Secondary Analyses in Obesity, Diabetes and Digestive and Kidney Diseases (R21) - PA-15-169

Organization: NIDDK 

Posting Date: 04-01-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) encourages R21 applications that propose to conduct secondary analyses of existing data sets relevant to diabetes and selected endocrine and metabolic diseases including thyroid, parathyroid and Cushings diseases and acromegaly; and genetic metabolic disease including cystic fibrosis, lysosomal storage diseases, and disorders of the urea cycle, amino acid metabolism and metal transport where the focus is on peripheral metabolism or organ function; obesity, liver diseases, alimentary GI tract diseases and nutrition; kidney, urologic, and hematologic diseases. The goal of this program is to facilitate research that explores innovative hypotheses through the use of existing data sets. 

Pilot and Feasibility Studies in Preparation for Drug and Alcohol Abuse Prevention Trials (R34) - PA-15-177

Organization: NIDA 

Posting Date: 04-07-2015 

Expiration Date: 01-25-2018 

Activity Code: R34 

Summary: This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving andthe drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and (b) pre-trial feasibility testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of early stage efficacy, effectiveness or services research that will provide intervention pilot and/or feasibility data that is a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols; rather, any development work must be imbedded within a pilot/feasibility study.Of particular interest are prevention interventions targeting the healthcare system.  

Pilot Health Services and Economic Research on the Treatment of Drug, Alcohol, and Tobacco Abuse (R34) - PA-15-250

Organization: NIDA 

Posting Date: 05-08-2015 

Expiration Date: 01-25-2018 

Activity Code: R34 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to encourage pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies, designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches.  

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R03) - PA-15-252

Organization: NIDA 

Posting Date: 05-08-2015 

Expiration Date: 01-25-2018 

Activity Code: R03 

Summary: This Funding Opportunity Announcement (FOA) encourages small grant applications (R03) to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.  

Health Services and Economic Research on the Prevention and Treatment of Drug, Alcohol, and Tobacco Abuse (R21) - PA-15-253

Organization: NIDA 

Posting Date: 05-08-2015 

Expiration Date: 01-25-2018 

Activity Code: R21 

Summary: This Funding Opportunity Announcement (FOA) encourages R21 grant applications to conduct rigorous health services and economic research to maximize the delivery of efficient, high-quality drug, tobacco, and alcohol prevention, treatment, and recovery support services. Examples of such research include: (1) clinical quality improvement; (2) quality improvement in services organization and management; (3) implementation research; (4) economic and cost studies; and (5) development or improvement of research methodology, analytic approaches, and measurement instrumentation used in the study of drug, alcohol, and tobacco prevention, treatment, and recovery services.  

Identification of Genetic and Genomic Variants by Next-Gen in Sequencing Non-human Animal Models (U01) - PAR-15-120

Organization: NIDA 

Posting Date: 02-13-2015 

Expiration Date: 03-02-2018 

Activity Code: U01 

Summary: The goals of this initiative are to identify gene variants of traits associated with addiction and substance abuse in selectively bred, and outbred non-human animal models using methodologies of Next Gen-Sequencing, mapping, and genotyping. This FOA will replace PAR-14-010 "Identification of Gene Variants for Addiction Related Traits by Next-Gen Sequencing in Model Organisms Selectively Bred for Addiction Traits (UH2/UH3)" 

Fast-Track Development of Medications to Treat Cannabis Use Disorders (UG3/UH3) - PAR-15-267

Organization: NIDA 

Posting Date: 05-26-2015 

Expiration Date: 05-08-2018 

Activity Code: UH2/UH3 

Summary: The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the discovery and development of medications to treat Cannabis Use Disorders (CUDs) using the UG3/UH3 mechanism. The objective is to advance medications toward the ultimate goal of obtaining FDA approval. Advances in understanding the cannabinoid systems and the effects of marijuana on the brain, coupled with the availability of both novel and marketed medications that may be efficacious to treat these disorders, offer unprecedented opportunities to develop safe and effective pharmacotherapies for CUDs. 

NeuroNEXT Infrastructure Resource Access (X01) - PAR-15-195

Organization: NINDS 

Posting Date: 04-30-2015 

Expiration Date: 01-24-2018 

Activity Code: X01 

Summary: This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm). Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol.  

Current Search

Refine Your Results

Program Announcements (PAs)

Parent Announcments Only

Requests for Applications (RFAs)

Issuing Only

All Organizations

AHRQ

CDC

DHHS

DOJ

EPA

FDA

FIC

HRSA

NASA

NCATS

NCBDDD

NCCDPHP

NCCIH

NCEH

NCHSTP

NCI

NCID

NCIPC

NCMHD

NCPHI

NCRR

NEI

NHGRI

NHLBI

NIA

NIAAA

NIAID

NIAMS

NIBIB

NICHD

NIDA

NIDCD

NIDCR

NIDDK

NIEHS

NIGMS

NIH

NIMH

NIMHD

NINDS

NINR

NIOSH

NIP

NLM

OAR

OBSSR

OD

ODP

ODS

OPHR

ORD

ORI

ORIP

ORWH

OSC

Roadmap

SAMHSA

*On or After
*On or After
(e.g. "K" for K01 or K02, K05, etc.)
Back to Top